Last updated: February 20, 2026
What is the case about?
ABBVIE INC. filed patent infringement lawsuit against APOTEX INC. in the District of New Jersey on March 25, 2025 (D.N.J. 3:25-cv-18972). The case involves patent rights related to AbbVie’s biologic drug, HUMIRA (adalimumab). ABBVIE claims that APOTEX’s biosimilar product infringes upon its patent estate covering HUMIRA, specifically targeting U.S. Patent Nos. 8,916,157 and 9,358,258.
What patents are involved?
Patent Nos.:
- 8,916,157: Covering methods of making adalimumab compositions.
- 9,358,258: Covering formulations of adalimumab with specific excipients.
Key claims:
- Patent 8,916,157 protects the process of producing adalimumab with reduced aggregation.
- Patent 9,358,258 covers stable formulations with specific buffer components.
What are the allegations?
ABBVIE alleges that APOTEX’s proposed biosimilar infringes these patents by manufacturing and planning to market a biosimilar adalimumab product in the U.S. without license or authorization. The complaint asserts patent infringement under 35 U.S.C. § 271(a) and (b). ABBVIE seeks injunctive relief, damages, and attorneys' fees.
Procedural posture
Initial filings:
- Complaint filed March 25, 2025.
- ABBVIE seeks a preliminary injunction to prevent APOTEX from marketing the biosimilar pending resolution.
Legal actions:
- ABBVIE has not requested a temporary restraining order; the case is in the early discovery phase.
- No summary judgment motions have been filed.
Industry context and patent landscape
Humira patents:
- ABBVIE maintains a large patent estate extending beyond the original issuance to encompass formulation, process, and method claims.
- The patent estate is critical to extending market exclusivity.
- Several patents expired in 2023, but key process and formulation patents remain enforceable.
Biosimilar market:
- Biosimilar manufacturers have launched or announced launches for adalimumab biosimilars in other jurisdictions since 2022.
- FDA approval processes for biosimilars require proof of biosimilarity and patent infringement clearance beforehand.
Strategic implications
- The case emphasizes the ongoing legal battle over biologic drug patents, particularly in biosimilar commercialization.
- ABBVIE’s aggressive patent enforcement underscores efforts to defend market share from biosimilar entrants.
- APOTEX’s defense may involve invalidity claims, including patent non-infringement and challenging patent validity based on prior art.
Potential outcomes
Possible resolutions include:
- Settlement via licensing agreement.
- Approval of biosimilar after patent challenge, if invalidity is established.
- Continuation of litigation leading to a court ruling on patent validity and infringement.
Impact on market:
- An adverse ruling could delay APOTEX’s biosimilar launch.
- A decision favoring APOTEX could open the U.S. market to biosimilar competition rapidly.
Key legal considerations
- Patent validity challenges: The case may involve arguments under 35 U.S.C. § 102 (anticipation) and § 103 (obviousness).
- Infringement analysis: Claim construction will determine infringement scope.
- Section 271(a): Direct infringement through manufacturing and sale.
- Section 271(b): Inducing infringement if APOTEX’s actions encourage infringement.
Litigation schedule impacts
- Early stages likely involve document production and claim construction hearings.
- No specified trial date; proceedings could extend into 2026 or beyond depending on motions and appeals.
- The outcome may influence other patent litigations involving similar biologics and biosimilars.
Summary
ABBVIE’s patent infringement suit against APOTEX underscores the strategic use of patent protections for biologic drugs against biosimilar competition. The case focuses on process and formulation patents critical to Humira’s exclusivity. The resolution may impact product availability, market share, and future biosimilar patent strategies.
Key Takeaways
- ABBVIE alleges infringement of key patents covering manufacturing and formulations of Humira.
- The case represents a common scenario in biologic biosimilar entry barriers.
- Patent validity and infringement issues will be central to the case’s progression.
- Litigation remains in early stages; outcomes could influence market entry timelines.
- Patent disputes in biologics continue to be a primary method for originators to extend exclusivity.
FAQs
1. When was the lawsuit filed?
March 25, 2025.
2. What patents are at the core of the dispute?
U.S. Patent Nos. 8,916,157 and 9,358,258.
3. What remedies is ABBVIE seeking?
Injunctive relief, damages, and attorneys' fees.
4. How could this case influence the biosimilar market?
A ruling invalidating patents could accelerate biosimilar availability; validity upheld could delay entry.
5. What are common defenses APOTEX might raise?
Patent invalidity (prior art, obviousness), non-infringement, or claim construction arguments.
References
[1] U.S. Patent and Trademark Office. (2023). Patent number information.
[2] Food and Drug Administration. (2022). Biosimilar approvals and guidance.
[3] Bloomberg Law. (2025). Litigation filings in biologic patent disputes.
